絞り込み

16644

広告

いくらあれば革命起こせる ネット資金調達先駆者の本気 (朝日新聞)

拡大する移転した新しいオフィスはガラス張り。「光が入る空間が良かった。気持ちまで明るくなる。今日も会社に来てがんばろうって思える、会社に行きたくなるオフィス」=...

  1. 時代の変化を映した改正薬機法、薬局・薬剤...
  2. 専門家なら怒鳴られても薬を早く出すな (...
  3. これからの時代の薬剤師はDon’t wa...
  4. 竹のストロー、インドの山村に根差す持続可...

ニュース一覧

Targeted delivery of lysosomal enzymes to the endocytic compartment in human cells using engineered extracellular vesicles.

著者 Do MA , Levy D , Brown A , Marriott G , Lu B
Sci Rep.2019 Nov 21 ; 9(1):17274.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (27view , 0users)

Full Text Sources

Targeted delivery of lysosomal enzymes to the endocytic compartment of human cells represents a transformative technology for treating a large family of lysosomal storage diseases (LSDs). Gaucher disease is one of the most common types of LSDs caused by mutations to the lysosomal β-glucocerebrosidase (GBA). Here, we describe a genetic strategy to produce engineered exosomes loaded with GBA in two different spatial configurations for targeted delivery to the endocytic compartment of recipient cells. By fusing human GBA to an exosome-anchoring protein: vesicular stomatitis virus glycoprotein (VSVG), we demonstrate that the chimeric proteins were successfully integrated into exosomes which were secreted as extracellular vesicles (EVs) by producer cells. Isolation and molecular characterization of EVs confirmed that the fusion proteins were loaded onto exosomes without altering their surface markers, particle size or distribution. Further, enzyme-loaded exosomes/EVs added to cultured medium were taken up by recipient cells. Further, the endocytosed exosomes/EVs targeted to endocytic compartments exhibited a significant increase in GBA activity. Together, we have developed a novel method for targeting and delivery of lysosomal enzymes to their natural location: the endocytic compartment of recipient cells. Since exosomes/EVs have an intrinsic ability to cross the blood-brain-barrier, our technology may provide a new approach to treat severe types of LSDs, including Gaucher disease with neurological complications.
PMID: 31754156 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード